Study details
Enrolling now
A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1
Cerus Corporation
NCT IDNCT07015437ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
70
Study length
about 1.1 years
Ages
18+
Locations
2 sites in OH, VA
About this study
Researchers are testing a new blood product called INTERCEPT. It involves infusing healthy volunteers with INTERCEPT red blood cells, which are prepared using the INTERCEPT Blood System. The trial will last 391 days and measure how well these new red blood cells work after being stored for 35 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Infusion of autologous radiolabeled RBCs
- 2.Use INTERCEPT Blood System for RBCs
PhasePhase 2
Routeintravenous
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low12%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug routes
intravenous